[Monoamines and choreic syndromes].
D000588:Amines / Q000378:metabolism*; D002090:Butyrophenones / Q000627:therapeutic use; D002819:Chorea / Q000139:chemically induced / Q000378:metabolism*; D003975:Diazepam / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000009:adverse effects; D004298:Dopamine / Q000378:metabolism; D005724:Ganglia / Q000503:physiopathology; D005917:Globus Pallidus / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy / Q000378:metabolism; D001523:Mental Disorders / Q000188:drug therapy; D008750:Methyldopa / Q000627:therapeutic use; D008781:Methyltyrosines / Q000627:therapeutic use; D008959:Models, Neurological; D009069:Movement Disorders / Q000139:chemically induced / Q000503:physiopathology; D010640:Phenothiazines / Q000627:therapeutic use; D010830:Physostigmine / Q000627:therapeutic use; D012110:Reserpine / Q000627:therapeutic use; D013788:Thalamus / Q000378:metabolism; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D014443:Tyrosine / Q000009:adverse effects
D000588:Amines; D002090:Butyrophenones; D008781:Methyltyrosines; D010640:Phenothiazines; D014149:Tranquilizing Agents; D014443:Tyrosine; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D010830:Physostigmine; D003975:Diazepam; D004298:Dopamine; D006719:Homovanillic Acid
Monoamines et syndromes choréiques.